MedOncMD

To provide the information your oncologist is not telling you or doesn't have the time to!

  • Home
  • Blog
    • The essentials
    • Art of Oncology
    • Prevention and Healthy Lifestyle
    • Research Advances
    • Navigation Corner
    • Video Library
  • Meet and Greet
    • About Dr Thomas
    • About Dr Landau
  • Ask MedOncMD?
  • 🧠 How I Create My Blog Posts

Breakthrough in Advanced Cervical Cancer Treatment: FDA Approves Pembrolizumab with Chemo

In the ongoing battle against cervical cancer, a ray of hope emerges with the FDA’s recent approval of a groundbreaking treatment approach. For women grappling with advanced stages of this disease, this marks a significant advancement, offering new possibilities in their treatment journey. Understanding Cervical Cancer: Cervical cancer, a malignancy arising in the cervix, presents …

Read On »

Navigating the Grey Zones of Medical Opinion

In medicine, biases, whether implicit or explicit, can significantly impact patient care. These biases might manifest as preconceived notions or preferences that subtly influence treatment recommendations. In the case of a patient of mines with metastatic GIST who developed acute renal failure secondary to an obstructing pelvis mass, a consulting urologist on call suggested to …

Read On »

Tarlatamab: A New Hope in Small-Cell Lung Cancer Treatment – Insights from the Phase 2 DeLLphi-301 Trial

New data published in NEJM may new treatment options for patients dealing with metastatic small cell carcinoma! Small-cell lung cancer (SCLC) stands as one of the most aggressive forms of cancer, often leaving patients and their families grappling with limited treatment options and a prognosis that can seem disheartening. But amidst these challenges, there emerges …

Read On »

Ensuring Continuous Care: Understanding How Your Oncology Team Manages During Physician Time Off

I recently took a trip with my family for about two weeks.  It is always a bit nerve wracking to take off for some personal time given that there are so many moving parts in any given day.   I wrote this post to remind patients and their families that no matter where your oncologist may …

Read On »

FDA Approves Powerful Duo: Enfortumab Vedotin-ejfv with Pembrolizumab

If you or a loved one is battling locally advanced or metastatic urothelial cancer (la/mUC), there’s groundbreaking news to share. On December 15, 2023, the Food and Drug Administration (FDA) gave the green light to a dynamic combination of treatments: enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda). This approval is especially significant for patients ineligible for …

Read On »

Belzutifan FDA Approval: A New Hope for Advanced Renal Cell Carcinoma Patients

On December 14, 2023, the FDA gave the green light to belzutifan (Welireg, Merck & Co., Inc.), offering new hope for individuals battling advanced kidney cancer. It’s like unlocking a powerful tool after trying different strategies. Understanding Belzutifan’s Power Against Kidney Cancer Imagine your body as a bustling city with the kidneys playing the role …

Read On »

Family at the Bedside: Why It Matters for Hospitalized Cancer Patients

Amongst my medical oncology colleagues, we each do about two months a year rounding with the inpatient team of fellows, residents, students, pharmacists, and extenders for either the inpatient medical oncology or hematology service. So any cancer patient admitted to our hospital system will often be seen by these two teams. In addition, I often …

Read On »

FDA Grants Accelerated Approval to Pirtobrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Empowering Hope: A Breakthrough in CLL/SLL Treatment On December 1, 2023, the Food and Drug Administration (FDA) delivered a beacon of hope by granting accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company). This approval is a significant stride in the treatment landscape for adults facing chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) …

Read On »

FDA Approval of Eflornithine for High-Risk Neuroblastoma Patients Marks a Milestone in Pediatric Oncology

On December 13, 2023, the Food and Drug Administration (FDA) achieved a significant breakthrough by granting approval to eflornithine (IWILFIN, USWM, LLC) for use in both adult and pediatric patients facing the challenges of high-risk neuroblastoma (HRNB). This groundbreaking decision marks the first-ever FDA approval of a therapy designed to reduce the risk of relapse …

Read On »

Information Overload in the Oncology Patient

This message comes from Ashlee Jones, our dedicated nurse navigator specializing in melanoma and sarcoma. She is held in high regard by our entire team, including nurses, pharmacists, staff, research professionals, and physicians! I’ve consistently believed that patients newly diagnosed with cancer may face a challenging beginning to their journey, given the unfamiliar diagnosis, the …

Read On »

  • Previous
  • Page 1
  • …
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • …
  • Page 28
  • Next

Recent Posts

  • When the System Works: A TIL Therapy Story
  • The Next Generation of TIL Therapy Has Arrived — And It Skips the IL-2
  • A Third Chance for RP1: An Option Melanoma Patients Still Need
  • The BRAF Pathway to TIL Program: Why Earlier Planning May Change the Treatment Journey for Melanoma Patients
  • The TIL Journey: From a Medical Oncologist’s Perspective

Categories

  • Art of Oncology (99)
  • Current News (17)
  • Immunotherapy News (13)
  • Navigation Corner (6)
  • Prevention and Healthy Lifestyle (18)
  • Reflections (3)
  • Research Advances (121)
    • Clinical Trials (52)
    • Immunotherapy (33)
    • New Treatments and Therapies (44)
  • The essentials (41)
    • Radiology (4)
  • Travel Health (1)
  • Uncategorized (10)
  • Varied Cancer Perspectives (127)
    • Biliary tract cancer (3)
    • Bladder Cancer (3)
    • Breast Cancer (10)
    • Cervical Cancer (2)
    • CNS Cancers (1)
    • Colorectal cancer (15)
    • Esophageal Cancer (2)
    • Gastric cancer (6)
    • Hepatic Tumors (1)
    • Leiomyosarcoma (2)
    • Leukemia (3)
    • Lung Cancer (11)
    • Lymphoma (3)
    • Melanoma (35)
    • Multiple Myeloma (3)
    • Neuroendocrine cancer (2)
    • Ovarian Cancer (3)
    • Pancreatic Cancer (5)
    • Prostate Cancer (5)
    • Sarcoma (2)
    • Sickle Cell Disease (4)
    • Skin Cancer (9)
    • Thyroid cancer (1)
    • Urothelial Cancer (1)
  • Video (2)
  • Weekly Newsletter (6)

Get in touch!

  • Facebook
  • Instagram
  • TikTok
  • LinkedIn


Meet the authors

Dr. Sajeve Thomas
Dr Daniel Landau


Subscribe


  • Home
  • Blog
    • The essentials
    • Art of Oncology
    • Prevention and Healthy Lifestyle
    • Research Advances
    • Navigation Corner
    • Video Library
  • Meet and Greet
    • About Dr Thomas
    • About Dr Landau
  • Ask MedOncMD?
  • 🧠 How I Create My Blog Posts
© 2026 MedOncMD. Minimal Theme by SPYR
✕
  • Home
  • Blog
    • The essentials
    • Art of Oncology
    • Prevention and Healthy Lifestyle
    • Research Advances
    • Navigation Corner
    • Video Library
  • Meet and Greet
    • About Dr Thomas
    • About Dr Landau
  • Ask MedOncMD?
  • 🧠 How I Create My Blog Posts